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Abstract
The present study, comprising a prospective multicentre study
including 53 non-neutropenic patients from intensive care units
(ICU) in six Spanish tertiary-care hospitals, was carried out to
determine the clinical signiﬁcance and inﬂuence on mortality of
Candida albicans germ tube-speciﬁc antibodies (CAGTA). There
were 22 patients (41.5%) for whom the CAGTA results were
positive, although none of had a blood culture positive for
Candida. The intra-ICU mortality rate was signiﬁcantly lower
(p = 0.004) in CAGTA-positive patients (61.2% vs. 22.7%).
Multivariate analysis conﬁrmed that a positive CAGTA result
was the only protective factor to be independently associated
with ICU mortality (b coefﬁcient = )0.3856; 95% conﬁdence
interval = )0.648 to )0.123).
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The mortality rate of invasive candidiasis (IC) remains exces-
sively high [1] and is associated with the difﬁculty of making
a prompt microbiological diagnosis [2] and a delay in antifun-
gal treatment [3,4]. To date, no single serological test has
demonstrated widespread clinical acceptance [5]. An immu-
noﬂuorescence assay (Candida albicans IFA IgG; Vircell, Gra-
nada, Spain) was recently commercialized for C. albicans
germ tube-speciﬁc antibody (CAGTA) detection. The pres-
ent study aimed to determine the positive result rate of
CAGTA testing in critically-ill patients and to assess its diag-
nostic and prognostic usefulnesses in this setting.
A prospective observational multicentre study was con-
ducted at six Spanish University hospitals over a 2-year per-
iod (2005 to 2006). Inclusion criteria were: (i) acute
pancreatitis of >7 days of disease evolution; (ii) prolonged
intensive care unit (ICU) stay (>14 days) in conjunction with
‡3 risk factors (e.g. diabetes mellitus, extra-renal depuration,
parenteral nutrition, >7 days of broad-spectrum antibiotic
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therapy, major abdominal surgery); (iii) liver transplant, (iv)
neutropenia or bone marrow transplant (BMT); and (v) high-
level Candida colonization. Exclusion criteria were: (i) preg-
nancy, (ii) age <18 years, (iii) previous IC, and (iv) life expec-
tancy <7 days. A corrected colonization index (CCI) was
used to assess the intensity of Candida colonization [6], and
patients with CCI ‡0.4 were considered to be highly colo-
nized. CAGTA detection (C. albicans IFA IgG; Vircell) was
performed twice weekly, with a serum titre ‡1/160 in at
least one sample considered to be a positive result. Blood
cultures were processed with automated systems (BACTEC,
Becton-Dickinson Biosciences, Franklin Lakes, NJ, USA;
BacTAlert, bioMe´rieux, Barcelona, Spain). Identiﬁcation of
yeasts was performed with API 32C or Vitek systems (bio-
Me´rieux). At each institution, the decision to initiate antifun-
gal therapy for patients with suspected IC was made at the
discretion of the prescribing physician, based on clinical crite-
ria, but it was not inﬂuenced by the results of the CAGTA
TABLE 1. Clinical and serological characteristics of patients included in the study
Patient
number Age Sex
Inclusion
criteria* Highest CCI
Serum
samples (No.)
Highest
CAGTA titre
Antifungal
treatment
CAGTA + titre
kinetics OutcomeTotal Positive
1 74 M 2 0.3 1 0 <1/80 No Death
2 52 F 2 0.0 2 0 <1/80 Yes Survival
3 51 M 2 0.3 3 0 <1/80 No Survival
4 71 M 2 0.3 4 0 <1/80 No Survival
5 77 F 2/5 0.8 2 1 1/160 Yes ﬂ Death
6 78 F 1/2 0.8 6 6 1/640 Yes ﬂ Survival
7 75 M 2 0.3 2 2 1/640 No M Survival
8 82 M 5 0.5 4 0 <1/80 Yes Death
9 74 M 5 0.6 1 0 <1/80 No Survival
10 64 M 2 0.3 1 1 1/160 No NA Death
11 45 M 4 0.5 3 0 <1/80 No Survival
12 69 F 4 0.8 3 0 <1/80 No Death
13 63 F 4 0.3 5 0 <1/80 No Death
14 75 M 2 0.0 3 0 <1/80 Yes Death
15 83 M 2 0.0 2 2 1/2560 Yes › Survival
16 79 F 5 0.8 3 0 <1/80 No Survival
17 71 M 2 0.0 9 9 1/2560 Yes ﬂ Death
18 51 M 3 1.0 3 1 1/320 Yes › Survival
19 53 F 2 0.0 2 1 1/160 No › Survival
20 59 M 5 0.4 8 0 <1/80 Yes Death
21 53 M 5 0.6 6 0 <1/80 Yes Survival
22 70 F 2 0.0 1 0 <1/80 No Death
23 61 M 2 0.0 1 0 <1/80 No Death
24 78 M 2 0.0 3 0 <1/80 Yes Death
25 62 M 1 0.0 1 0 <1/80 Yes Death
26 80 F 5 0.4 2 2 1/160 Yes M Death
27 45 F 5 0.5 4 1 1/160 Yes ﬂ Survival
28 62 M 2 0.3 2 2 1/320 Yes ﬂ Death
29 50 F 2 0.0 4 1 1/160 No ﬂ Survival
30 76 M 5 1.0 3 0 <1/80 Yes Survival
31 71 F 2 0.0 2 2 1/1280 Yes › Survival
32 67 M 2 0.0 1 0 <1/80 No Death
33 78 F 2 0.0 3 3 1/160 No M Survival
34 62 F 2 0.0 3 1 1/320 No › Survival
35 81 F 2 0.0 1 0 1/80 No Survival
36 81 M 2 0.0 3 0 1/80 Yes Death
37 31 M 2 0.0 2 2 1/1280 No › Death
38 26 M 2 0.0 2 1 1/160 Yes › Survival
39 60 M 2/3/4 0.8 2 0 1/80 No Death
40 55 F 2 0.5 5 1 1/160 No ﬂ Survival
41 35 M 1/2 0.4 3 3 1/160 Yes M Survival
42 101 M 2 0.5 3 2 1/320 No ﬂ Survival
43 79 F 2 0.0 1 1 1/1280 No NA Survival
44 64 M 2/5 0.8 1 0 1/80 Yes Death
45 32 M 3 0.3 2 2 1/320 No M Survival
46 46 F 2 0.5 2 0 1/80 Yes Death
47 71 M 2/5 0.5 5 0 1/80 Yes Death
48 18 M 2 0.6 3 0 1/80 Yes Survival
49 79 M 2/5 0.8 2 0 1/80 Yes Survival
50 73 F 2 0.0 6 0 1/80 Yes Death
51 59 M 2/5 0.6 6 0 <1/80 Yes Survival
52 64 F 2 0.0 1 0 1/80 Yes Death
53 61 M 2 0.3 3 0 1/80 No Survival
M, male; F, female; CCI, corrected colonization index.
Inclusion criteria: *1: acute pancreatitis of more than seven days of evolution; *2: prolonged ICU stay (>14 days) and three or more risk factors (diabetes mellitus. extra-renal
depuration, parenteral nutrition, >7 days of broad spectrum antibiotic therapy, and major abdominal surgery); *3: liver transplant; *4: neutropenia or bone marrow transplant;
and *5: high Candida colonization.
›: increasing titres; M: no change; ﬂ: decreasing titres; NA, not applied.
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assay. Chi-square or Fisher’s exact tests were used to com-
pare categorical variables. Multivariate analysis was per-
formed to determine independent predictors of related
intra-ICU candidaemia mortality using the stepwise method.
p <0.05 was considered statistically signiﬁcant.
Fifty-three critically ill patients were included in the
study (Table 1). The most frequent inclusion criteria were
prolonged ICU stay and the presence of ‡3 IC risk factors
(60%), followed by CCI ‡0.4 (23%) and neutropenia or
BMT (7.5%). Age and APACHE II score averages were
71.5 ± 18.4 years, and 14.9 ± 5.4 points, respectively. The
major reasons for ICU admission were septic shock
(28.3%) and respiratory failure (28.3%). Patient characteris-
tics did not differ among the participating centres.
Culture-based methods yielded negative results for yeasts
in all patients.
Twenty-two patients (41.5%) had CAGTA-positive results
(ten patients had one positive sample, eight patients had
two, and four patients had greater than or equal to three).
CAGTA titres were in the range of 1/160 to 1/2560. The
presence of acute renal failure (ARF) was more frequent in
CAGTA-negative patients. The APACHE II score was statisti-
cally higher in this group.
Intra-ICU mortality was 45.2%, being signiﬁcantly lower
(p = 0.025) in CAGTA-positive patients (22.7% vs. 61.2% in
CAGTA-negative patients). Higher APACHE II score, ARF,
and CAGTA-negativity were also associated with ICU mor-
tality in the univariate analysis (Table 2). Conversely, surgi-
cal patients were signiﬁcantly associated with a better
outcome.
CAGTA positivity, APACHE II score, and the use of anti-
fungal therapy were introduced into the multivariate statisti-
cal model as dependent variables. The stepwise method
conﬁrmed a CAGTA-positive result as a protective factor
and the only independent variable associated with intra-ICU
mortality (b coefﬁcient = )0.3856; 95% conﬁdence inter-
val = )0.648 to )0.123).
Ponton et al. [7–9] have developed an indirect immuno-
ﬂuorescence assay to detect CAGTA, which proved useful
in the diagnosis of IC in different groups of patients [10–
13]. The test has shown an overall sensitivity of 77–89%
and a speciﬁcity of 91–100%. CAGTA has been detected
in patients with IC due to Candida species other than
C. albicans [9,12–15]. The C. albicans IFA IgG test has been
compared with the standard test in a retrospective study
using 172 sera from 51 haematology and ICU patients
[13]. The commercially available test was similar to the
standard test and provided a faster and easier diagnosis of
IC.
The sensitivity and speciﬁcity of CAGTA detection have
not been established in the present study because all blood
cultures performed for Candida spp. were negative. The high
prevalence of CAGTA-positive results obatained (41.5%)
corroborates the adequacy of the inclusion criteria used in
the present study as a predictive biomarker of Candida infec-
tion and the need to consolidate data concerning CAGTA
detection in a well-deﬁned ICU population.
Although the global sensitivity rate of blood culture is not
too high (approximately 50%) in the hospital population [16],
this procedure remains the reference standard for candide-
mia diagnosis. However, this ratio is considerably lower in
the ICU setting (5.7%), as previously observed in a Candida
score study [17].
The univariate analysis conﬁrmed the APACHE II score,
ARF, and diabetes mellitus as mortality risk factors. To our
knowledge, no association between a positive serological
result and mortality has been reported previously in a pro-
spective study in ICU patients with IC. However, the signiﬁ-
cance of antibody responses to other antigens (especially
heat shock proteins) has been reported previously in animal
models [18,19].
Intra-ICU mortality was signiﬁcantly lower in CAGTA-
positive patients. Although CAGTA-positive and -negative
patients received antifungal treatment based on clinical data,
the lower mortality observed in the CAGTA-positive group
might be related to correct empirical treatment. Moreover,
immunological responses could also play a role in the high
mortality of CAGTA-negative patients.
Several limitations of the present study should be noted.
First, the small number of patients is a limitation as a result
of the difﬁculty of enrolling this kind of patient with prede-
ﬁned criteria. Moreover, it was not possible to establish the
sensitivity and speciﬁcity of the CAGTA technique as a result
TABLE 2. Univariate analysis of intensive care unit
mortality
Number of patients (%)
p valueSurvival Died
Age (years) 68.6 ± 21.7 75 ± 15.3 0.20
Male/Female (ratio) 1.57 2 0.56
APACHE II (score) 12.9 ± 5.2 17 ± 4.7 0.005
Septic shock 6 (20.7) 9 (37.5) 0.17
Respiratory failure 9 (31) 6 (25) 0.62
Coma 2 (6.9) 3 (12.5) 0.48
Renal failure 8 (27.6) 16 (66.7) 0.004
Extra-renal depuration 6 (20.7) 10 (41.7) 0.09
Hepatic failure 8 (27.6) 9 (37.5) 0.44
Neutropenia 1 (3.4) 3 (12.5) 0.21
Antifungal treatment 13 (44.8) 14 (58.3) 0.32
CAGTA+ 17 (58.6) 5 (20.8) 0.006
Diabetes mellitus 4 (13.8) 8 (33.3) 0.09
Previous surgery 16 (55.2) 4 (16.7) 0.004
Total 29 (100) 24 (100) –
CAGTA+, Detection of Candida albicans germ tube antibodies.
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of the absence of proven IC. The possible bias due to the
APACHE II score mismatch between groups needs to be
evaluated with tested specimens.
One-third of non-survivors had only a single specimen
tested, whereas 90% of survivors had serial specimens
tested. One possible explanation of this mismatch could be
that the higher APACHE scores resulted in an earlier mor-
tality, before serial samples could be collected and before
antibody positivity had developed. However, its effect on
mortality was not conﬁrmed in the multivariate analysis.
In conclusion, the rate of positive CAGTA results
recorded in a selected group of ICU patients was mark-
edly higher than theoretically expected. Based on these
results, a strategy of early antifungal treatment after
CAGTA detection might reduce the ICU mortality of
those individuals with risk factors for the development of
IC. Further studies are warranted to conﬁrm these initial
ﬁndings.
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